keyword
MENU ▼
Read by QxMD icon Read
search

Severe treatment resistant major depression

keyword
https://www.readbyqxmd.com/read/29179735/ficus-sycomorus-extract-reversed-behavioral-impairment-and-brain-oxidative-stress-induced-by-unpredictable-chronic-mild-stress-in-rats
#1
Harquin Simplice Harquin Foyet, Serge Tchinda Deffo, Pascaline Koagne Yewo, Iulia Antioch, Stéphane Zingue, Emmanuel Acha Asongalem, Pierre Kamtchouing, Alin Ciobica
BACKGROUND: Stress, regardless of its nature is nowadays recognized as one of the major risk factors for neuropsychiatric diseases, such as mood and anxiety disorders. The brain compared with other organs is more vulnerable to oxidative damage mainly due to its high rate of oxygen consumption, abundant lipid content, and relative insufficiency of antioxidant enzymes. Thus, the identification of neural mechanisms underlying resistance and vulnerability to stress is of crucial importance in understanding the pathophysiology of neuropsychiatric disorders and in developing new treatments, since the existing ones are for several reasons subject to increasing limitations...
November 28, 2017: BMC Complementary and Alternative Medicine
https://www.readbyqxmd.com/read/29166316/the-impact-of-repetitive-transcranial-magnetic-stimulation-on-oxidative-stress-in-subjects-with-medication-resistant-depression
#2
Onur Durmaz, Emre İspir, Hayriye Baykan, Murat Alişik, Özcan Erel
OBJECTIVES: Recent studies have shown that oxidative stress is involved in the neurobiology of depression. We investigated the effects of repetitive transcranial magnetic stimulation (rTMS) on a novel oxidative stress marker, thiol-disulfide homeostasis, in subjects with medication-resistant major depression (MRD). METHODS: Twenty-six subjects with MRD underwent 15 rTMS sessions. Sociodemographic and baseline and post-rTMS Montgomery-Asberg Depression Rating Scale (MADRS) data were collected...
November 21, 2017: Journal of ECT
https://www.readbyqxmd.com/read/29119217/psilocybin-with-psychological-support-for-treatment-resistant-depression-six-month-follow-up
#3
R L Carhart-Harris, M Bolstridge, C M J Day, J Rucker, R Watts, D E Erritzoe, M Kaelen, B Giribaldi, M Bloomfield, S Pilling, J A Rickard, B Forbes, A Feilding, D Taylor, H V Curran, D J Nutt
RATIONALE: Recent clinical trials are reporting marked improvements in mental health outcomes with psychedelic drug-assisted psychotherapy. OBJECTIVES: Here, we report on safety and efficacy outcomes for up to 6 months in an open-label trial of psilocybin for treatment-resistant depression. METHODS: Twenty patients (six females) with (mostly) severe, unipolar, treatment-resistant major depression received two oral doses of psilocybin (10 and 25 mg, 7 days apart) in a supportive setting...
November 8, 2017: Psychopharmacology
https://www.readbyqxmd.com/read/29115994/exploring-venlafaxine-pharmacokinetic-variability-with-a-phenotyping-approach-a-multicentric-french-swiss-study-marvel-study
#4
Célia Lloret-Linares, Youssef Daali, Sylvie Chevret, Isabelle Nieto, Fanny Molière, Philippe Courtet, Florence Galtier, Raphaëlle-Marie Richieri, Sophie Morange, Pierre-Michel Llorca, Wissam El-Hage, Thomas Desmidt, Frédéric Haesebaert, Philippe Vignaud, Jerôme Holtzmann, Jean-Luc Cracowski, Marion Leboyer, Antoine Yrondi, Fabienne Calvas, Liova Yon, Philippe Le Corvoisier, Olivier Doumy, Kyle Heron, Damien Montange, Siamak Davani, Julien Déglon, Marie Besson, Jules Desmeules, Emmanuel Haffen, Frank Bellivier
BACKGROUND: It is well known that the standard doses of a given drug may not have equivalent effects in all patients. To date, the management of depression remains mainly empirical and often poorly evaluated. The development of a personalized medicine in psychiatry may reduce treatment failure, intolerance or resistance, and hence the burden and costs of mood depressive disorders. The Geneva Cocktail Phenotypic approach presents several advantages including the "in vivo" measure of different cytochromes and transporter P-gp activities, their simultaneous determination in a single test, avoiding the influence of variability over time on phenotyping results, the administration of low dose substrates, a limited sampling strategy with an analytical method developed on DBS analysis...
November 7, 2017: BMC Pharmacology & Toxicology
https://www.readbyqxmd.com/read/29111404/a-systematic-review-and-meta-analysis-on-placebo-response-to-repetitive-transcranial-magnetic-stimulation-for-depression-trials
#5
Laís B Razza, Adriano H Moffa, Marina L Moreno, Andre F Carvalho, Frank Padberg, Felipe Fregni, André R Brunoni
BACKGROUND: Although several studies indicate that placebo response is large to antidepressant pharmacotherapy in major depressive disorder (MDD), no updated meta-analysis has quantified the magnitude of the placebo (sham) response to repetitive transcranial magnetic stimulation (rTMS) in MDD yet. OBJECTIVE: To conduct a systematic review and meta-analysis on this issue in randomized controlled trials (RCTs) involving participants with MDD; and to explore potential moderators...
February 2, 2018: Progress in Neuro-psychopharmacology & Biological Psychiatry
https://www.readbyqxmd.com/read/29106789/depression-and-obstructive-sleep-apnea
#6
(no author information available yet)
OBJECTIVE: Obstructive sleep apnea (OSA), is described as intermittent interruptions or reductions in airflow which are initiated by an incomplete or complete collapse of the upper airways despite respiratory effort. When left untreated, OSA is connected with comorbid conditions, such as cardiovascular and metabolic illnesses. METHOD: The PubMed database was used to examine papers published until April 2017 using the subsequent terms: "obstructive sleep apnea" or "obstructive sleep apnoea" and "depression" in successive combination with "CPAP (continuous positive airway pressure)", "therapy", "pharmacotherapy", "psychotherapy", "cognitive behavioral therapy" or "quality of life"...
October 6, 2017: Neuro Endocrinology Letters
https://www.readbyqxmd.com/read/29101798/cytokine-serum-levels-remain-unchanged-during-lithium-augmentation-of-antidepressants-in-major-depression
#7
Roland Ricken, Marlene Busche, Peter Schlattmann, Hubertus Himmerich, Sandra Bopp, Tom Bschor, Christoph Richter, Thomas J Stamm, Andreas Heinz, Rainer Hellweg, Undine E Lang, Mazda Adli
Lithium augmentation (LA) of antidepressants is a first-line therapy in treatment-resistant depression. Immunomodulatory effects of lithium have been described. The cytokine hypothesis of depression postulates that cytokines play a key role in the pathophysiology of depression. Concordantly, it has been shown that proinflammatory cytokine serum levels decrease during antidepressant treatment. The aim of this study was to investigate changes in cytokine serum levels during LA. Serum concentrations of the cytokines interleukin (IL)-2, IL-4, IL-6, IL-8, IL-10, tumour necrosis factor alpha, interferon-gamma, granulocyte and monocyte colony stimulating factor were measured in a total of 95 acutely depressed patients before and after four weeks of LA...
October 5, 2017: Journal of Psychiatric Research
https://www.readbyqxmd.com/read/29101095/smartphone-cognitive-behavioral-therapy-as-an-adjunct-to-pharmacotherapy-for-refractory-depression-randomized-controlled-trial
#8
Akio Mantani, Tadashi Kato, Toshi A Furukawa, Masaru Horikoshi, Hissei Imai, Takahiro Hiroe, Bun Chino, Tadashi Funayama, Naohiro Yonemoto, Qi Zhou, Nao Kawanishi
BACKGROUND: In the treatment of major depression, antidepressants are effective but not curative. Cognitive behavioral therapy (CBT) is also effective, alone or in combination with pharmacotherapy, but accessibility is a problem. OBJECTIVE: The aim is to evaluate the effectiveness of a smartphone CBT app as adjunctive therapy among patients with antidepressant-resistant major depression. METHODS: A multisite, assessor-masked, parallel-group randomized controlled trial was conducted in 20 psychiatric clinics and hospitals in Japan...
November 3, 2017: Journal of Medical Internet Research
https://www.readbyqxmd.com/read/29093685/bipolar-spectrum-disorders-in-male-youth-the-interplay-between-symptom-severity-inflammation-steroid-secretion-and-body-composition
#9
REVIEW
Andreas Walther, Marlene Penz, Daniela Ijacic, Timothy R Rice
The morbidity and societal burden of youth bipolar spectrum disorders (BSD) are high. These disorders are multisystemic in that adult populations there are clear interactions with inflammatory processes and steroidal physiological systems. There are much less data concerning these areas of study in youth populations with BSD. This is surprising given the association of youth-onset BSD with puberty and its associated physiological changes. In this mini-review, we overview the theoretical role of inflammatory processes and steroidal physiological systems in youth BSD, describe the greater literature in adult populations, detail the literature in youth populations when available, and overview current proposed molecular mechanistic pathways and interaction effects based on the available data...
2017: Frontiers in Psychiatry
https://www.readbyqxmd.com/read/29063521/blunted-amygdala-activity-is-associated-with-depression-severity-in-treatment-resistant-depression
#10
Jamie Ferri, Stuart J Eisendrath, Susanna L Fryer, Erin Gillung, Brian J Roach, Daniel H Mathalon
Up to 50% of individuals with major depressive disorder (MDD) do not recover after two antidepressant medication trials, and therefore meet the criteria for treatment-resistant depression (TRD). Mindfulness-based cognitive therapy (MBCT) is one promising treatment; however, the extent to which MBCT influences clinical outcomes relative to baseline neural activation remains unknown. In the present study we investigated baseline differences in amygdala activation between TRD patients and healthy controls (HCs), related amygdala activation to depression symptoms, and examined the impacts of MBCT and amygdala activation on longitudinal depression outcomes...
October 23, 2017: Cognitive, Affective & Behavioral Neuroscience
https://www.readbyqxmd.com/read/29059135/pramipexole-and-electroconvulsive-therapy-in-treatment-resistant-depression
#11
Claire Gauthier, Lama Souaiby, Emmanuelle Advenier-Iakovlev, Raphaël Gaillard
BACKGROUND: Major depressive disorder (MDD) is a common disease. Despite appropriate antidepressant treatment, approximately one third of patients do not achieve adequate response. In these patients, electroconvulsive therapy (ECT) is a possible option. Nevertheless, some symptoms may persist even after ECT. METHOD: This is a comparative retrospective study assessing the efficacy and safety of pramipexole in the treatment of resistant depression, in combination to ECT or after a partial ECT efficacy...
November 2017: Clinical Neuropharmacology
https://www.readbyqxmd.com/read/28962608/benefits-of-home-based-multidisciplinary-exercise-and-supportive-care-in-inoperable-non-small-cell-lung-cancer-protocol-for-a-phase-ii-randomised-controlled-trial
#12
Lara Edbrooke, Sanchia Aranda, Catherine L Granger, Christine F McDonald, Mei Krishnasamy, Linda Mileshkin, Louis Irving, Sabine Braat, Ross A Clark, Ian Gordon, Linda Denehy
BACKGROUND: Lung cancer is one of the most commonly diagnosed cancers, and is a leading cause of cancer mortality world-wide. Due to lack of early specific symptoms, the majority of patients present with advanced, inoperable disease and five-year relative survival across all stages of non-small cell lung cancer (NSCLC) is 14%. People with lung cancer also report higher levels of symptom distress than those with other forms of cancer. Several benefits for survival and patient reported outcomes are reported from physical activity and exercise in other tumour groups...
September 29, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28900387/social-isolation-in-early-versus-late-adolescent-mice-is-associated-with-persistent-behavioral-deficits-that-can-be-improved-by-neurosteroid-based-treatment
#13
Andrea Locci, Philippe Geoffroy, Michel Miesch, Ayikoe-Guy Mensah-Nyagan, Graziano Pinna
Early trauma and stress exposure during a critical period of life may increase the risk of major depressive disorder (MDD) and post-traumatic stress disorder (PTSD) in adulthood. The first-choice treatment for MDD and PTSD are selective serotonin reuptake inhibitor (SSRI) antidepressants. Unfortunately, half of MDD and PTSD patients show resistance to the therapeutic effects of these drugs and more efficient treatments are essential. Both MDD and PTSD patients present reduced levels of allopregnanolone (Allo), a potent endogenous positive allosteric modulator of GABA action at GABAA receptors which are normalized by SSRIs in treatment responders...
2017: Frontiers in Cellular Neuroscience
https://www.readbyqxmd.com/read/28881501/drug-drug-interaction-potential-in-men-treated-with-enzalutamide-mind-the-gap
#14
G E Benoist, I M van Oort, S Smeenk, A Javad, D M Somford, D M Burger, N Mehra, N P van Erp
AIM: Metastatic castration resistant prostate cancer (mCRPC) patients are generally older patients with several co-morbidities and are therefore more at risk for complications due to drug-drug interactions(DDIs). We assessed the prevalence of potential DDIs in a cohort of mCRPC patients treated with enzalutamide. METHODS: We conducted a retrospective review of pharmacy records to retrieve individual drug histories of mCRPC patients who started enzalutamide therapy in a tertiary care setting...
September 7, 2017: British Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/28822460/-french-society-for-biological-psychiatry-and-neuropsychopharmacology-and-fondation-fondamental-task-force-formal-consensus-for-the-management-of-treatment-resistant-depression
#15
T Charpeaud, J-B Genty, S Destouches, A Yrondi, S Lancrenon, N Alaïli, F Bellivier, D Bennabi, T Bougerol, V Camus, T D'amato, O Doumy, F Haesebaert, J Holtzmann, C Lançon, M Lefebvre, F Moliere, I Nieto, R Richieri, L Schmitt, F Stephan, G Vaiva, M Walter, M Leboyer, W El-Hage, E Haffen, P-M Llorca, P Courtet, B Aouizerate
Major depression represents among the most frequent psychiatric disorders in the general population with an estimated lifetime prevalence of 16-17%. It is characterized by high levels of comorbidities with other psychiatric conditions or somatic diseases as well as a recurrent or chronic course in 50 to 80% of the cases leading to negative repercussions on the daily functioning, with an impaired quality of life, and to severe direct/indirect costs. Large cohort studies have supported that failure of a first-line antidepressant treatment is observed in more than 60% of patients...
September 2017: L'Encéphale
https://www.readbyqxmd.com/read/28758582/potential-novel-treatments-for-bipolar-depression-ketamine-fatty-acids-anti-inflammatory-agents-and-probiotics
#16
G H Vázquez, S Camino, L Tondo, Ross J Baldessarini
BACKGROUND: Treatments for depression in bipolar disorder (BD) are far less well developed than for unipolar major depressive disorder. Several innovative and experimental approaches have been emerging recently, including use of the dissociative anesthetic ketamine and other antagonists of central NMDA glutamate receptors, as well as unsaturated fatty acids, anti-inflammatory agents, and possibly probiotic methods. METHODS: We reviewed relevant reports from the past decade...
July 28, 2017: CNS & Neurological Disorders Drug Targets
https://www.readbyqxmd.com/read/28744230/primary-sjogren-s-syndrome-associated-with-treatment-resistant-obsessive-compulsive-disorder
#17
Lawrence T C Ong, Gary Galambos, David A Brown
There is an increasing awareness that autoimmune diseases can present with neuropsychiatric manifestations. We present the case of a 17-year-old female requiring psychiatric hospitalization for obsessive-compulsive disorder and major depressive disorder with mixed affective features, who was subsequently diagnosed with primary Sjogren's syndrome. Treatment with potent immunosuppression resulted in remission of psychiatric illness. Due to a lack of awareness and/or the lack of specific biomarkers, clinicians may not associate psychiatric symptoms with autoimmune disease, including primary Sjogren's syndrome...
2017: Frontiers in Psychiatry
https://www.readbyqxmd.com/read/28723697/the-history-and-future-of-ablative-neurosurgery-for-major-depressive-disorder
#18
Matthew Volpini, Peter Giacobbe, G Rees Cosgrove, Anthony Levitt, Andres M Lozano, Nir Lipsman
BACKGROUND: There is an urgent need to develop safe and effective treatments for patients with treatment-resistant depression (TRD). Several neurosurgical procedures have been developed to treat the dysfunctional brain circuits implicated in major depression. OBJECTIVES: This review describes the most common ablative procedures used to treat major depressive disorder: anterior cingulotomy, subcaudate tractotomy, limbic leucotomy, and anterior capsulotomy. The efficacy and safety of each are discussed and compared with other current and emerging modalities, including deep brain stimulation (DBS) and MR-guided focused ultrasound (MRgFUS)...
2017: Stereotactic and Functional Neurosurgery
https://www.readbyqxmd.com/read/28714751/antidepressant-efficacy-of-electroconvulsive-therapy-is-associated-with-a-reduction-of-the-innate-cellular-immune-activity-in-the-cerebrospinal-fluid-in-patients-with-depression
#19
Laura Kranaster, Carolin Hoyer, Suna S Aksay, Jan Malte Bumb, Norbert Müller, Peter Zill, Markus J Schwarz, Alexander Sartorius
OBJECTIVES: A bidirectional link between the antidepressant effects of electroconvulsive therapy (ECT) and the modulation of the immune system has been proposed. To elucidate the interplay between antidepressant treatment and macrophage/microglia activation in humans, we performed a study on the effects of the antidepressant treatment by ECT on markers of macrophage/microglia activation in patients with depression. METHODS: We measured six different markers (IL-6, neopterin, sCD14, sCD163 MIF and MCP1) of macrophage/microglia activation in the cerebrospinal fluid (CSF) and blood of 12 patients with a severe, treatment-resistant depressive episode before and after a course of ECT...
August 9, 2017: World Journal of Biological Psychiatry
https://www.readbyqxmd.com/read/28707590/combining-drug-and-psychological-treatments-for-obsessive-compulsive-disorder-what-is-the-evidence-when-and-for-whom
#20
Umberto Albert, Gabriele Di Salvo, Francesca Solia, Gianluca Rosso, Giuseppe Maina
BACKGROUND: serotonin reuptake inhibitors (SRIs) and cognitive-behavioral psychotherapy (CBT) are first-line treatments for obsessive-compulsive disorder (OCD). Since response is often inadequate, in recent years researchers investigated whether combining CBT and SRIs, either ab initio or sequentially, results in a greater reduction of obsessive-compulsive symptoms. OBJECTIVE: the aims of the present paper are to assess if combination treatment seems adding benefits as compared to either monotherapy alone and if sequential strategies may be effective in converting partial or non responders to a first-line treatment into responders...
July 12, 2017: Current Medicinal Chemistry
keyword
keyword
74573
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"